SAN DIEGO, California, USA, June 1, 2026
Oncolytics Biotech has announced encouraging preclinical findings for pelareorep in combination with RAS-targeted therapies, providing new evidence that the company’s investigational immunotherapy may enhance anti-tumor activity in some of the most challenging cancer types. The early-stage research demonstrated that combining pelareorep with various RAS inhibitor modalities produced greater anti-tumor effects than either treatment approach alone, supporting further investigation in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) models. The findings strengthen the scientific rationale for combining immune-based therapies with targeted oncology treatments and highlight pelareorep’s potential role as an immune-priming backbone for future cancer treatment strategies. As resistance to targeted therapies continues to limit long-term patient outcomes, the results could represent an important step toward improving treatment durability in RAS-mutated tumors.
Pelareorep Shows Enhanced Anti-Tumor Activity with RAS Inhibitors
The initial preclinical study evaluated pelareorep alongside several RAS-targeting approaches in solid tumor models. Researchers observed evidence that the combination generated stronger anti-tumor responses than either pelareorep or RAS inhibitors used independently, suggesting a potential synergistic effect between immune activation and targeted pathway inhibition. Pelareorep is an investigational, intravenously delivered immunotherapeutic designed to stimulate anti-cancer immune responses through activation of innate and adaptive immunity.
The therapy promotes the production of inflammatory cytokines, encourages the formation of tertiary lymphoid structures, and increases the presence of tumor-infiltrating lymphocytes, all of which are considered critical components of effective anti-tumor immunity. By enhancing immune recognition of cancer cells, pelareorep may help overcome one of the biggest challenges in oncology: the development of resistance to targeted therapies.
Focus Expands to Pancreatic and Colorectal Cancer Models
Advertisement
Building on these positive findings, Oncolytics plans to initiate additional studies in pancreatic and colorectal cancer models, two disease areas where RAS mutations are highly prevalent and treatment options remain limited. The company will evaluate pelareorep in combination with KRAS G12C inhibitors, pan-RAS inhibitors, and other next-generation RAS pathway-targeting agents.
Future studies are specifically designed to investigate immune activation, durability of tumor response, and the ability of the combinations to delay or prevent treatment resistance. Pancreatic cancer remains one of the deadliest malignancies worldwide, with nearly all tumors harboring alterations in the RAS signaling pathway. Similarly, colorectal cancer frequently develops resistance to targeted treatments over time. Researchers believe that integrating immune-based therapies such as pelareorep with precision oncology approaches could create a more durable and effective treatment paradigm for patients with advanced disease.
Potential Implications for Future Cancer Treatment Strategies
The latest data add to growing evidence supporting pelareorep’s development across multiple gastrointestinal cancers. The therapy has previously demonstrated encouraging results in pancreatic, breast, anal, and colorectal cancer studies and has received FDA Fast Track designation for both pancreatic and colorectal cancer programs. Company leadership emphasized that the new findings reinforce pelareorep’s potential to convert immunologically “cold” tumors into “hot” tumors, thereby improving responsiveness to treatment and potentially extending patient benefit.
Full results from the current preclinical program are expected to be presented later in 2026 and may provide additional insights into the mechanisms driving the observed anti-tumor activity. If future studies confirm these early findings, pelareorep could emerge as a valuable combination partner for next-generation targeted therapies, particularly in difficult-to-treat cancers where therapeutic resistance remains a major obstacle. The program also supports broader industry efforts to combine immunotherapy and targeted medicine to improve outcomes for patients facing aggressive solid tumors.
Source: Oncolytics Biotech press release
